708 related articles for article (PubMed ID: 8161290)
1. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH
J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
Bogetto F; Bellino S; Vaschetto P; Ziero S
Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
[TBL] [Abstract][Full Text] [Related]
5. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
[TBL] [Abstract][Full Text] [Related]
6. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
7. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
8. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
McDougle CJ; Fleischmann RL; Epperson CN; Wasylink S; Leckman JF; Price LH
J Clin Psychiatry; 1995 Nov; 56(11):526-8. PubMed ID: 7592506
[TBL] [Abstract][Full Text] [Related]
9. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
[TBL] [Abstract][Full Text] [Related]
10. Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder.
Husted DS; Shapira NA; Murphy TK; Mann GD; Ward HE; Goodman WK
J Psychiatr Res; 2007; 41(3-4):332-7. PubMed ID: 16860338
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of fluvoxamine combined with extended-release methylphenidate on treatment-refractory obsessive-compulsive disorder].
Zheng H; Jia F; Guo G; Quan D; Li G; Huang H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Nov; 43(11):1230-1235. PubMed ID: 30643068
[TBL] [Abstract][Full Text] [Related]
12. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
Askari N; Moin M; Sanati M; Tajdini M; Hosseini SM; Modabbernia A; Najand B; Salimi S; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
CNS Drugs; 2012 Oct; 26(10):883-92. PubMed ID: 22873680
[TBL] [Abstract][Full Text] [Related]
13. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study.
Arabzadeh S; Shahhossenie M; Mesgarpour B; Rezaei F; Shalbafan MR; Ghiasi Z; Akhondzadeh S
Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28485008
[TBL] [Abstract][Full Text] [Related]
14. [Treatment-refractory OCD from the viewpoint of obsessive-compulsive spectrum disorders: impact of comorbid child and adolescent psychiatric disorders].
Kano Y
Seishin Shinkeigaku Zasshi; 2013; 115(9):990-6. PubMed ID: 24228477
[TBL] [Abstract][Full Text] [Related]
15. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.
McDougle CJ; Goodman WK; Leckman JF; Holzer JC; Barr LC; McCance-Katz E; Heninger GR; Price LH
Am J Psychiatry; 1993 Apr; 150(4):647-9. PubMed ID: 8465885
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.
Goodman WK; Price LH; Rasmussen SA; Delgado PL; Heninger GR; Charney DS
Arch Gen Psychiatry; 1989 Jan; 46(1):36-44. PubMed ID: 2491940
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
[TBL] [Abstract][Full Text] [Related]
18. Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder.
McDougle CJ; Goodman WK; Price LH
J Clin Psychiatry; 1994 Mar; 55 Suppl():24-31. PubMed ID: 7521326
[TBL] [Abstract][Full Text] [Related]
19. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
Ghaleiha A; Entezari N; Modabbernia A; Najand B; Askari N; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
J Psychiatr Res; 2013 Feb; 47(2):175-80. PubMed ID: 23063327
[TBL] [Abstract][Full Text] [Related]
20. L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
Nematizadeh M; Ghorbanzadeh H; Moghaddam HS; Shalbafan M; Boroon M; Keshavarz-Akhlaghi AA; Akhondzadeh S
Psychiatry Clin Neurosci; 2023 Sep; 77(9):478-485. PubMed ID: 37169515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
